SEC Company Response from AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Feb 28, 2018
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: Feb. 28, 2018 · CIK: 0001385818 · Accession: 0001213900-18-002387
AI Filing Summary & Sentiment
File numbers found in text: 333-222994
Show Raw Text
CORRESP
1
filename1.htm
Joseph Gunnar & Co., LLC
30 Broad Street, 11th Floor, New York,
NY 10004
February 28, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
100 F St., NE
Washington, D.C. 20549
Attention: Irene Paik
Re: Aytu Bioscience, Inc.
Registration Statement on Form S-1
(File No. 333-222994)
Ladies and Gentlemen:
Pursuant to Rule 461 of the General
Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Joseph Gunnar
& Co., LLC, as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced
Registration Statement so that it will become effective at 5:00 p.m. Eastern Time on March 1, 2018, or as soon thereafter as practicable.
Pursuant to Rule 460 under the
Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited
to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to
be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned confirms that
it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that
they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in
connection with the above-referenced issue.
Very truly yours,
Joseph Gunnar & Co., LLC
By:
/s/ Eric Lord
Name: Eric Lord
Title: Head of Investment Banking / Underwritings